doi: 10.23137/AOM24.03.PP0001 BibTeX RIS Mendeley


위고비® 오남용: 비만 약물 치료 방향과 정책에 대한 제언

Wegovy® Misuse: Suggestions on the Direction and Policy for Obesity Treatment

  • 가은 (고려대학교 의과대학 고려대학교 구로병원 가정의학과)
  • 경곤 (가천대학교 의과대학 가천대 길병원 가정의학과)

초록

Wegovy®, an anti-obesity medication approved in South Korea in April 2023, has attracted attention for its significant weight loss and cardiovascular benefits. However, concerns regarding its misuse have arisen since its release. The drug is being prescribed through telemedicine and sold illegally online, often to individuals without obesity who seek it for cosmetic purposes, and sometimes without proper medical supervision. This misuse increases the risk of serious side effects, including gastrointestinal issues and potential complications such as cholecystitis and pancreatitis. Furthermore, the misuse of Wegovy® exacerbates health inequalities. Due to distorted pricing, patients who truly need the treatment may have to pay additional costs beyond the appropriate price, or face difficulty accessing the drug together. This situation can create disparities in access to medication based on socioeconomic status. Health authorities should recognize obesity as a chronic condition that significantly impacts public health. They should seriously consider policy changes to provide health insurance coverage for obesity treatment and medication, especially for individuals with severe cases. Stricter regulations on online sales, telemedicine prescriptions, and increased public awareness are also essential to prevent misuse and improve access for those in genuine need. Additionally, continuous monitoring of drug usage and adverse events is crucial to ensure its proper use. Ultimately, a collaborative effort from the medical community, the public, and health authorities is necessary to ensure the appropriate use of Wegovy®, minimize health risks, and improve equitable access to treatment for obesity.


키워드

Wegovy®, Semaglutide, Misuse, Obesity treatment, Policy, Health insurance coverage


발행 정보.

서지정보
비만대사연구학술지 / v.3, no.2, 2024, pp.51-54
발행기관
대한가정의학회 비만대사증후군연구회
pISSN
2951-0333
eISSN
2951-0597
발행일
2024.12.31

이력 정보

2024.12.30 DOI 등록
2024.12.31 발행

위치 정보


다른 형식